To Be Discontinued Injection Hematology
Tbo-filgrastim Injection · 455 days since initial FDA posting
Brand: GRANIX
FDA lists Tbo-filgrastim Injection as To Be Discontinued (Teva Pharmaceuticals USA, Inc.).
No availability text on this FDA row.
Tbo-filgrastim Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Tbo-filgrastim Injection
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)
- Package NDC
- 63459-920-59
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jun 13, 2025
- Last Updated
- Jun 13, 2025
- Therapeutic Category
- Hematology
Row fields from the FDA Drug Shortages database via openFDA.